IQVIA Advocates for Streamlined Early Clinical Development in Congressional Testimony
Event summary
- Dr. Cynthia Verst, President of Design and Delivery Innovation at IQVIA, testified before the U.S. House Committee on Energy and Commerce Subcommittee on Health on July 16, 2026.
- Verst proposed recommendations to modernize early clinical development in the U.S., focusing on efficiency without compromising patient safety standards.
- Key proposals included establishing minimum datasets for first-in-human studies, enabling flexible FDA interactions, and expanding access to scientific advice for emerging biopharmaceutical companies.
The big picture
IQVIA's testimony aligns with broader industry efforts to reduce barriers in early clinical development, particularly for emerging biotech firms that drive a significant portion of new Phase I trials. The push for regulatory modernization reflects growing pressure to maintain U.S. leadership in biomedical innovation amid increasing global competition.
What we're watching
- Regulatory Efficiency
- How the FDA will respond to IQVIA's proposals for more flexible, iterative interactions during early clinical development.
- Biotech Funding
- Whether emerging biopharmaceutical companies can secure staged investment more easily with streamlined regulatory pathways.
- Infrastructure Development
- The pace at which the U.S. strengthens its bench-to-clinic infrastructure to support faster translation of scientific discoveries into treatments.
Related topics